Evidence map›Paper›PMID 38672734›Full record

ArticleLife (Basel, Switzerland)2024

Correlation between Trabecular Bone Score and Homocysteine Level in Rheumatoid Arthritis Patients on Anti-TNF Inhibitors.

Florentina Ioniță-Radu, Iulia-Nadine Nicolau, Oana-Georgiana Petrache, Maria-Laura Groșeanu, Violeta-Claudia Bojincă, Maria-Magdalena Negru, Sandica Bucurică, Daniela Anghel

Open access · goldAbstract read
In one paragraph

Article in Life (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
4.7field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Florentina Ioniță-RaduDepartment of Gastroenterology, Dr. Carol Davila Central Military Emergency University Hospital, 010825 Bucharest, Romania.ORCID 0000-0001-9829-5035
Iulia-Nadine NicolauDepartment of Internal Medicine 2, Dr. Carol Davila University Central Military Emergency Hospital, 010825 Bucharest, Romania.
Oana-Georgiana PetracheDepartment of Internal Medicine 2, Dr. Carol Davila University Central Military Emergency Hospital, 010825 Bucharest, Romania.
Maria-Laura GroșeanuDepartment of Rheumatology, Carol Davila University of Medicine and Pharmacy, 020021 Bucharest, Romania.
Violeta-Claudia BojincăDepartment of Rheumatology, Carol Davila University of Medicine and Pharmacy, 020021 Bucharest, Romania.
Maria-Magdalena NegruDepartment of Rheumatology, Carol Davila University of Medicine and Pharmacy, 020021 Bucharest, Romania.
Sandica BucuricăDepartment of Gastroenterology, Dr. Carol Davila Central Military Emergency University Hospital, 010825 Bucharest, Romania.ORCID 0000-0002-8787-3829
Daniela AnghelDepartment of Internal Medicine 2, Dr. Carol Davila University Central Military Emergency Hospital, 010825 Bucharest, Romania.
Carol Davila University of Medicine and Pharmacy · ROUniversity of Science and Technology of China · CNTitu Maiorescu University · RO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Rheumatoid arthritis (RA) is an independent osteoporosis risk factor. Biologic and immunosuppressive treatment, and levels of homocysteine and 25-OH vitamin D may influence the trabecular bone score (TBS) in RA patients. We aimed to compare the effects of biological (b) and conventional synthetic (cs) disease-modifying anti-rheumatic drugs (DMARDs) on TBS in patients with RA and hyperhomocysteinemia (HHcy) or 25-OH vitamin D deficiency. Patients who had tests conducted for trabecular bone score, bone mineral density (BMD), homocysteine (Hcy) and 25-OH vitamin D at an interval of one year and met the inclusion criteria were enrolled in this retrospective study. Sixty-four patients with RA were enrolled and were divided into the following two groups: the first group (34 patients) had received treatment with bDMARDs and the second group (30 patients) had received csDMARDs. BDMARDs and csDMARDs had a positive influence on TBS and BMD. The best results were observed in the Adalimumab group (

Indexed as

25-OH vitamin Danti-TNF α agentsbone mineral densityhomocysteinerheumatoid arthritistrabecular bone score

Identifiers

PMID38672734
PMCPMC11051517
OpenAlexW4393487337

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.